A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control

Marilyn L Barrett, Jay K Udani, Marilyn L Barrett, Jay K Udani

Abstract

Obesity, and resultant health hazards which include diabetes, cardiovascular disease and metabolic syndrome, are worldwide medical problems. Control of diet and exercise are cornerstones of the management of excess weight. Foods with a low glycemic index may reduce the risk of diabetes and heart disease as well as their complications. As an alternative to a low glycemic index diet, there is a growing body of research into products that slow the absorption of carbohydrates through the inhibition of enzymes responsible for their digestion. These products include alpha-amylase and glucosidase inhibitors. The common white bean (Phaseolus vulgaris) produces an alpha-amylase inhibitor, which has been characterized and tested in numerous clinical studies. A specific and proprietary product named Phase 2® Carb Controller (Pharmachem Laboratories, Kearny, NJ) has demonstrated the ability to cause weight loss with doses of 500 to 3000 mg per day, in either a single dose or in divided doses. Clinical studies also show that Phase 2 has the ability to reduce the post-prandial spike in blood glucose levels. Experiments conducted incorporating Phase 2 into food and beverage products have found that it can be integrated into various products without losing activity or altering the appearance, texture or taste of the food. There have been no serious side effects reported following consumption of Phase 2. Gastro-intestinal side effects are rare and diminish upon extended use of the product. In summary, Phase 2 has the potential to induce weight loss and reduce spikes in blood sugar caused by carbohydrates through its alpha-amylase inhibiting activity.

References

    1. World Health Organization. Obesity and overweight. 2006. Ref Type: Online Source.
    1. Preuss HG. Bean amylase inhibitor and other carbohydrate absorption blockers: effects on diabesity and general health. J Am Coll Nutr. 2009;28:266–276.
    1. Obiro WC, Zhang T, Jiang B. The nutraceutical role of the Phaseolus vulgaris alpha-amylase inhibitor. Br J Nutr. 2008;100:1–12. doi: 10.1017/S0007114508879135.
    1. Food and Agriculture Organization, World Health Organization. Carbohydrates in Human Nutrition: Report of a Joint FAO/WHO Report. FAO Food and Nutrition paper. 1998;66:1–140.
    1. Radulian G, Rusu E, Dragomir A, Posea M. Metabolic effects of low glycaemic index diets. Nutr J. 2009;8:5. doi: 10.1186/1475-2891-8-5.
    1. Yamagishi S, Matsui T, Ueda S, Fukami K, Okuda S. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. Curr Drug Metab. 2009;10:159–163. doi: 10.2174/138920009787522133.
    1. Brand-Miller J, McMillan-Price J, Steinbeck K, Caterson I. Dietary glycemic index: health implications. J Am Coll Nutr. 2009;28:446S–449S.
    1. Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P. et al.Glycemic index, glycemic load, and chronic disease risk--a meta-analysis of observational studies. Am J Clin Nutr. 2008;87:627–637.
    1. Thomas DE, Elliott EJ, Baur L. Low glycaemic index or low glycaemic load diets for overweight and obesity. Cochrane Database Syst Rev. 2007. p. CD005105.
    1. Krishnan S, Rosenberg L, Singer M, Hu FB, Djousse L, Cupples LA. et al.Glycemic index, glycemic load, and cereal fiber intake and risk of type 2 diabetes in US black women. Arch Intern Med. 2007;167:2304–2309. doi: 10.1001/archinte.167.21.2304.
    1. Villegas R, Liu S, Gao YT, Yang G, Li H, Zheng W. et al.Prospective study of dietary carbohydrates, glycemic index, glycemic load, and incidence of type 2 diabetes mellitus in middle-aged Chinese women. Arch Intern Med. 2007;167:2310–2316. doi: 10.1001/archinte.167.21.2310.
    1. Schulze MB, Liu S, Rimm EB, Manson JE, Willett WC, Hu FB. Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr. 2004;80:348–356.
    1. Schulze MB, Schulz M, Heidemann C, Schienkiewitz A, Hoffmann K, Boeing H. Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. Arch Intern Med. 2007;167:956–965. doi: 10.1001/archinte.167.9.956.
    1. Englyst KN, Englyst HN. Carbohydrate bioavailability. Br J Nutr. 2005;94:1–11. doi: 10.1079/BJN20051457.
    1. Grabitske HA, Slavin JL. Low-digestible carbohydrates in practice. J Am Diet Assoc. 2008;108:1677–1681. doi: 10.1016/j.jada.2008.07.010.
    1. Higgins JA. Resistant starch: metabolic effects and potential health benefits. J AOAC Int. 2004;87:761–768.
    1. Tundis R, Loizzo MR, Menichini F. Natural products as alpha-amylase and alpha-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update. Mini Rev Med Chem. 2010;10:315–331. doi: 10.2174/138955710791331007.
    1. McDougall GJ, Stewart D. The inhibitory effects of berry polyphenols on digestive enzymes. Biofactors. 2005;23:189–195. doi: 10.1002/biof.5520230403.
    1. Koh LW, Wong LL, Loo YY, Kasapis S, Huang D. Evaluation of different teas against starch digestibility by mammalian glycosidases. J Agric Food Chem. 2010;58:148–154. doi: 10.1021/jf903011g.
    1. Moreno J, Altabella T, Chrispeels MJ. Characterization of alpha-Amylase-Inhibitor, a Lectin-Like Protein in the Seeds of Phaseolus vulgaris. Plant Physiol. 1990;92:703–709. doi: 10.1104/pp.92.3.703.
    1. Layer P, Carlson GL, DiMagno EP. Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans. Gastroenterology. 1985;88:1895–1902.
    1. Layer P, Zinsmeister AR, DiMagno EP. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. Gastroenterology. 1986;91:41–48.
    1. Strocchi A, Corazza GR, Anania C, Benati G, Malservisi S, Cherchi MV. et al.Quality control study of H2 breath testing for the diagnosis of carbohydrate malabsorption in Italy. The "Tenue Club" Group. Ital J Gastroenterol Hepatol. 1997;29:122–127.
    1. Strocchi A, Corazza G, Ellis CJ, Gasbarrini G, Levitt MD. Detection of malabsorption of low doses of carbohydrate: accuracy of various breath H2 criteria. Gastroenterology. 1993;105:1404–1410.
    1. Brummer RJ, Karibe M, Stockbrugger RW. Lactose malabsorption. Optimalization of investigational methods. Scand J Gastroenterol Suppl. 1993;200:65–69. doi: 10.3109/00365529309101578.
    1. Layer P, Rizza RA, Zinsmeister AR, Carlson GL, DiMagno EP. Effect of a purified amylase inhibitor on carbohydrate tolerance in normal subjects and patients with diabetes mellitus. Mayo Clin Proc. 1986;61:442–447.
    1. Brugge WR, Rosenfeld MS. Impairment of starch absorption by a potent amylase inhibitor. Am J Gastroenterol. 1987;82:718–722.
    1. Boivin M, Zinsmeister AR, Go VL, DiMagno EP. Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans. Mayo Clin Proc. 1987;62:249–255.
    1. Boivin M, Flourie B, Rizza RA, Go VL, DiMagno EP. Gastrointestinal and metabolic effects of amylase inhibition in diabetics. Gastroenterology. 1988;94:387–394.
    1. Jain NK, Boivin M, Zinsmeister AR, Brown ML, Malagelada JR, DiMagno EP. Effect of ileal perfusion of carbohydrates and amylase inhibitor on gastrointestinal hormones and emptying. Gastroenterology. 1989;96:377–387.
    1. Nicolosi R, Hughes D, Bechtel D. Evaluation of the Generally Recognized as Safe (GRAS) status of Phase 2® white bean (Phaseolus vulgaris) extract. Bridgewater, NJ, Cantox Health Sciences International; 2007. Ref Type: Online Source.
    1. Udani K. The mighty bean. European Baker. 2005.
    1. Das Y. Phase 2/Starch Lite. Piscataway, NJ, ISSI Laboratories, Inc; 2007. ISSI no. P25036, 1-7. Ref Type: Online Source.
    1. Das Y. Phase 2/Starch Lite in Chewing Gum. Piscataway, NJ, ISSI Laboratories, Inc; 2007. ISSI no. P25036-B, 1-4. Ref Type: Online Source.
    1. Celleno L, Tolaini MV, D'Amore A, Perricone NV, Preuss HG. A dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. Int J Med Sci. 2007;4:45–52.
    1. Rothacker D. Reduction in body weight with a starch blocking diet aid: StarchAway comparison with placebo. Leiner Health Products; 2003. Ref Type: Online Source.
    1. Wu X, Xu X, Shen J, Perricone N, Preuss H. Enhanced weight loss from a dietary supplement containing standardized Phaseolus vulgaris extract in overweight men and women. Journal of Applied Research. 2010;10:73–79.
    1. Udani J, Singh BB. Blocking carbohydrate absorption and weight loss: a clinical trial using a proprietary fractionated white bean extract. Altern Ther Health Med. 2007;13:32–37.
    1. Thom E. A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin. J Int Med Res. 2000;28:229–233.
    1. Erner S, Meiss D. Thera-Slim for Weight Loss: A randomized double-blind placebo controlled study. 2003. Ref Type: Online Source.
    1. Koike T, Koizumi Y, Tang L, Takahara K, Saitou Y. The antiobesity effect and the safety of taking "Phaseolamin(TM) 1600 diet". J New Rem & Clin (Japanese) 2005;54:1–16.
    1. Osorio L, Gamboa J. Random multicenter evaluation to test the efficacy of Phaseolus vulgaris (Precarb) in obese and overweight individuals. Internal Report; 2005. Ref Type: Online Source.
    1. Yamada J, Yamamoto T, Yamaguchi T. Effects of combination of functional food materials on body weight, body fat percentage, serum triglyceride and blood glucose. 2007. Ref Type: Online Source.
    1. Udani J, Hardy M, Madsen DC. Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract. Altern Med Rev. 2004;9:63–69.
    1. Vinson J, Al Kharrat H, Shuta D. Investigation of an amylase inhibitor on human glucose absorption after starch consumption. The Open Nutraceuticals Journal. 2009;2:88–91. doi: 10.2174/1876396000902010088.
    1. Udani JK, Singh BB, Barrett ML, Preuss HG. Lowering the glycemic index of white bread using a white bean extract. Nutr J. 2009;8:52. doi: 10.1186/1475-2891-8-52.
    1. Harikumar KB, Jesil AM, Sabu MC, Kuttan R. A preliminary assessment of the acute and subchronic toxicity profile of phase2: an alpha-amylase inhibitor. Int J Toxicol. 2005;24:95–102. doi: 10.1080/10915810590936364.
    1. Chokshi D. Subchronic oral toxicity of a standardized white kidney bean (Phaseolus vulgaris) extract in rats. Food Chem Toxicol. 2007;45:32–40. doi: 10.1016/j.fct.2006.06.021.
    1. Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus. 2009;2:i27–i36. doi: 10.1093/ndtplus/sfn177.
    1. Wiatr C. US Biosimilar Pathway Unlikely to be Useddagger: Developers Will Opt for a Traditional BLA Filing. BioDrugs. 2011;25:63–67. doi: 10.2165/11588410-000000000-00000.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner